Bagsværd, Denmark Tuesday, November 5, 2024, 10:00 Hrs [IST] ...

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...

Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH).

The Danish drugmaker plans to introduce a combination drug, CagriSema, that could result in 25% weight loss — higher than ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...

Novo Nordisk is scheduled to report results for the third quarter on Wednesday. Here is what you need to know: NET PROFIT FORECAST: Net profit in the quarter is expected to rise 19% to 26.79 billion ...

Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4 mg in treating MASH and ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...